Bladder cancer

Clinical practice guidelines in oncology

James E. Montie, Robert R. Bahnson, Samuel M. Cohen, Beverly Drucker, Mario A. Eisenberger, Rizk El-Galley, Harry W. Herr, Gary R. Hudes, Timothy M. Kuzel, Paul H. Lange, Anthony Patterson, Alan Pollack, Jerome P. Richie, John Seigne, William U. Shipley, Eric J. Small, Donald L. Trump, Philip J. Walther, Timothy G. Wilson

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

Original languageEnglish (US)
Pages (from-to)4-34
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number1
StatePublished - Jan 1 2005

Fingerprint

Practice Guidelines
Urinary Bladder Neoplasms
Organ Preservation
Recurrence
Therapeutics
Neoplasms
Radiotherapy
Quality of Life
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Montie, J. E., Bahnson, R. R., Cohen, S. M., Drucker, B., Eisenberger, M. A., El-Galley, R., ... Wilson, T. G. (2005). Bladder cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 3(1), 4-34.

Bladder cancer : Clinical practice guidelines in oncology. / Montie, James E.; Bahnson, Robert R.; Cohen, Samuel M.; Drucker, Beverly; Eisenberger, Mario A.; El-Galley, Rizk; Herr, Harry W.; Hudes, Gary R.; Kuzel, Timothy M.; Lange, Paul H.; Patterson, Anthony; Pollack, Alan; Richie, Jerome P.; Seigne, John; Shipley, William U.; Small, Eric J.; Trump, Donald L.; Walther, Philip J.; Wilson, Timothy G.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 3, No. 1, 01.01.2005, p. 4-34.

Research output: Contribution to journalReview article

Montie, JE, Bahnson, RR, Cohen, SM, Drucker, B, Eisenberger, MA, El-Galley, R, Herr, HW, Hudes, GR, Kuzel, TM, Lange, PH, Patterson, A, Pollack, A, Richie, JP, Seigne, J, Shipley, WU, Small, EJ, Trump, DL, Walther, PJ & Wilson, TG 2005, 'Bladder cancer: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 1, pp. 4-34.
Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R et al. Bladder cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2005 Jan 1;3(1):4-34.
Montie, James E. ; Bahnson, Robert R. ; Cohen, Samuel M. ; Drucker, Beverly ; Eisenberger, Mario A. ; El-Galley, Rizk ; Herr, Harry W. ; Hudes, Gary R. ; Kuzel, Timothy M. ; Lange, Paul H. ; Patterson, Anthony ; Pollack, Alan ; Richie, Jerome P. ; Seigne, John ; Shipley, William U. ; Small, Eric J. ; Trump, Donald L. ; Walther, Philip J. ; Wilson, Timothy G. / Bladder cancer : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2005 ; Vol. 3, No. 1. pp. 4-34.
@article{7ba9761daad44660b7b4f5ee169b1fdc,
title = "Bladder cancer: Clinical practice guidelines in oncology",
abstract = "Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.",
author = "Montie, {James E.} and Bahnson, {Robert R.} and Cohen, {Samuel M.} and Beverly Drucker and Eisenberger, {Mario A.} and Rizk El-Galley and Herr, {Harry W.} and Hudes, {Gary R.} and Kuzel, {Timothy M.} and Lange, {Paul H.} and Anthony Patterson and Alan Pollack and Richie, {Jerome P.} and John Seigne and Shipley, {William U.} and Small, {Eric J.} and Trump, {Donald L.} and Walther, {Philip J.} and Wilson, {Timothy G.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "3",
pages = "4--34",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Bladder cancer

T2 - Clinical practice guidelines in oncology

AU - Montie, James E.

AU - Bahnson, Robert R.

AU - Cohen, Samuel M.

AU - Drucker, Beverly

AU - Eisenberger, Mario A.

AU - El-Galley, Rizk

AU - Herr, Harry W.

AU - Hudes, Gary R.

AU - Kuzel, Timothy M.

AU - Lange, Paul H.

AU - Patterson, Anthony

AU - Pollack, Alan

AU - Richie, Jerome P.

AU - Seigne, John

AU - Shipley, William U.

AU - Small, Eric J.

AU - Trump, Donald L.

AU - Walther, Philip J.

AU - Wilson, Timothy G.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

AB - Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

UR - http://www.scopus.com/inward/record.url?scp=33745217393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745217393&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 4

EP - 34

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 1

ER -